We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The creation of nonprofit drugmakers could help remove the perverse incentives that keep generic drug prices high, three public health experts contend in a New England Journal of Medicine commentary. Read More
Former executives at Valeant and Philidor were convicted Tuesday of participating in a kickback scheme to ensure the drugmaker relied exclusively on Philidor for mail order pharmaceutical services. Read More
A group of physicians cited potential safety issues for patients who need to adjust the dosage of a drug they take based on side effects or its interactions with their other medications. Read More
Against a backdrop of widespread scrutiny of drug prices, Pharmacyclics opted to scrap a plan to triple the price of its blood cancer drug, Imbruvica (ibrutinib). Read More
Fresenius claimed it discovered “blatant fraud at the very top level of Akorn’s executive team [and] stunning evidence of blatant and pervasive data integrity violations,” after it had agreed to acquire the company last year — leading to its decision to pull out of the planned $4.3 billion deal. Read More
Opioid sales in the United States increased more than eightfold between 1992 and 2015, according to a new analysis by the FDA that found no clear links between price and volume. Read More
Pay-for-delay deals between branded and generic drugmakers in the European Union continued to decline in 2016, according to the latest update from the European Commission. Read More
Osiris Therapeutics filed a lawsuit against MiMedx Group for alleged theft of its clients and pre-paid commissions to Osiris’ longtime distributor Stability Biologics. Read More